PPARG and diabetes mellitus: TZDs, as PPARγ agonists, are increasingly being used to counteract the effects of diabetes by regulating the transcription of insulin-responsive genes, thereby enhancing insulin sensitivity in adipose tissue, skeletal muscle and liver to help reduce plasma glucose and insulin [26].